Executives And Founders Of Uber, Facebook And Apple Are Bullish On This Wellness App — You Can Coinvest At $1.15 Per Share

Aura Biosciences (NASDAQ:AURA) Azioni

AURA BIOSCIENCES INC

Aura Biosciences

Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.

Truist Securities analyst Michael Ciarmoli upgrades Astronics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRO#NASDAQ">ATRO</a>) from Hold to Buy and raises the price target from $32 to $49.

News

Upgrades

Price Target

Analyst Ratings

ATRO

Truist Securities Upgrades Astronics to Buy, Raises Price Target to $49

JMP Securities analyst Patrick Walravens reiterates Salesforce (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>) with a Market Outperform and maintains $430 price target.

Reiteration

JMP Securities Reiterates Market Outperform on Salesforce, Maintains $430 Price Target

Truist Securities analyst Lucas Servera upgrades GXO Logistics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GXO#NYSE">GXO</a>) from Hold to Buy and raises the price target from $48 to $62.

Truist Securities Upgrades GXO Logistics to Buy, Raises Price Target to $62

Keybanc analyst Justin Patterson maintains Spotify Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPOT#NYSE">SPOT</a>) with a Overweight and raises the price target from $640 to $860.

SPOT

Keybanc Maintains Overweight on Spotify Technology, Raises Price Target to $860

Telsey Advisory Group analyst Dana Telsey maintains Ulta Beauty (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULTA#NASDAQ">ULTA</a>) with a Outperform and maintains $520 price target.

ULTA

Telsey Advisory Group Maintains Outperform on Ulta Beauty, Maintains $520 Price Target

The agreement outlines a mutual interest in the following areas of cooperation:
<ul>
<li>Development of custom oracle feeds for real-world asset pricing and data &nbsp;</li>
<li>Implementation of real-time proof-of-reserve attestations &nbsp;</li>
<li>Joint go-to-market opportunities for RWA-related products 
<ul>
<li>Integration of Switchboard's oracle infrastructure into DeFi Dev Corp.'s RWA framework</li>
</ul>
</li>
</ul>

Contracts

DFDV

DeFi Development Signs Non-Binding Letter of Intent With Switchboard Technology Labs; To Explore Strategic Collaboration Across Solana Ecosystem

Upexi, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPXI#NASDAQ">UPXI</a>) (the "Company" or "Upexi"), a brand owner specializing in the development, manufacturing and distribution of consumer products with diversification into the cryptocurrency space, today announced that it has entered into securities purchase agreements with certain accredited investors, qualified purchasers and institutional investors, as well as with Allan Marshall, the Company's Chief Executive Officer, for the purchase and sale of 12,457,186 shares of common stock (or common stock equivalents in lieu thereof) at a price of $4.00 per share (and at a price of $4.94 per share for management's participation) for aggregate gross proceeds of approximately $50 million (the "Equity Offering"), before deducting placement agent fees and other offering expenses.
The closing of the Equity Offering is expected to occur on or about July 14, 2025, subject to the satisfaction of customary closing conditions. The Company expects to use a portion of the proceeds from the Equity Offering to fund the Company's existing business operations and for working capital and general corporate purposes, and the balance of the net proceeds shall be used to fund the Company's Solana treasury strategy.
The Company also announced that, concurrent with the Equity Offering, it has entered into additional securities purchase agreements with certain institutional investors and qualified purchasers for the purchase of Convertible Notes in exchange for locked and spot Solana with an&nbsp;aggregate original principal amount of approximate $150 million (the "Note Offering").
The Convertible Notes are collateralized by SOL provided by the respective holders. The Convertible Notes have an interest rate of 2.0% payable on a quarterly basis, a fixed conversion price of $4.25 per share and maturity of 24 months.

Offerings

UPXI

Upexi Raises $200M In Equity And Crypto-Backed Note Deals To Drive Product And Treasury Expansion

WIIM

GORV

Lazydays Holdings shares are trading lower on possible continued weakness after the company announced yesterday a 1-for-30 reverse stock split.

Scotiabank analyst Sung Ji Nam upgrades Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) from Sector Perform to Sector Outperform and announces $275 price target.

Scotiabank Upgrades Danaher to Sector Outperform, Announces $275 Price Target

BMNR

Bitmine Immersion Technologies shares are trading higher amid a rally in the price of Bitcoin to all-time highs.

The Southeastern African country has secured $12 billion in mining and infrastructure investments from China. The deals, signed under Malawi&#8217;s Minister of Mining, Ken Zikhale Reeves Ng'oma, could elevate the landlocked country in the global <a href="https://www.benzinga.com/markets/commodities">commodity value chain</a>.
The $12 billion package is divided into two transactions. The first is a $7 billion deal with China's Hunan Sunwalk Group to develop titanium mining and processing facilities in Salima, central Malawi. This largest-ever foreign investment includes commitments to technology transfer, local skills development and social infrastructure. Building the downstream mineral processing capacity is set to create thousands of jobs.
The second is a $5 billion agreement with Xidian International Stock Exchange, focused on establishing a Special Economic Zone (SEZ) in Chipoka, strategically located on the shores of Lake Malawi.
The SEZ will integrate mining, agri-industrial and infrastructure development with $1 billion worth of projects expected to launch in its first year. As a future logistics and processing hub, the SEZ will enable Malawi's role as a supplier of rare earths, titanium, graphite and uranium—minerals critical to clean energy technologies.
Despite a diverse mineral resource base, there are currently no significant operations, though several foreign operators are pursuing promising projects.
<ul class="wp-block-list">
<li>Lindian Resources (OTCPK: LINIF) is advancing the Kangankunde Rare Earths Project, which is backed by over $120 million in proposed funding from Ecobank, the European Investment Bank, and the Gerald Group. The project is slated to become one of the largest rare earth facilities globally upon its operational commencement in 2026.</li>
<li>Lotus Resources (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/LTSRF#OTCQX">LTSRF</a>) has secured $38.5 million from South African banks for the Kayelekera Uranium Project, targeting first production by the third quarter of 2025. This restart of the mine, acquired from Paladin Energy in 2020, positions Malawi as a notable uranium producer.</li>
<li>Sovereign Metals (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/SVMLF#OTCQX">SVMLF</a>), in partnership with Rio Tinto, is fast-tracking the Kasiya Rutile-Graphite Project, the world's largest known rutile deposit and second-largest graphite reserve. The site is expected to yield 245,000 tons of rutile and 288,000 tons of graphite annually, generating up to $16.4 billion in lifetime revenues.</li>
</ul>
Still, Malawi faces structural economic challenges, with a GDP heavily reliant on agriculture and aid, and the mining sector contributing just 1% to the economy. However, projections suggest mineral exports could reach $30 billion between 2026 and 2040, potentially raising mining's share of GDP to 10% by 2030.
The strategic Chinese investment points to the broader geopolitical balancing act. As Western-backed initiatives—such as the <a href="https://www.benzinga.com/markets/emerging-markets/24/10/41416913/bidens-farewell-to-africa-strategic-motives-behind-first-and-only-presidential-visit">Lobito Corridor modernization</a> in Angola and Zambia and <a href="https://www.benzinga.com/25/03/44216408/dr-congo-explores-a-minerals-for-security-deal-with-the-us">peacekeeping mineral agreements</a> with the DR Congo—gain traction, China is shoring up influence in Malawi, countering Western leverage in the region.
Minister Ng'oma is expected to reveal further details at the Critical Minerals Roundtable during African Mining Week, taking place October 1–3 in Cape Town, South Africa.
Read Next: <a href="https://www.benzinga.com/markets/commodities/25/07/46339702/trumps-copper-tariff-echoes-through-global-mining-tunnels">Trump&#8217;s Copper Tariff Echoes Through Global Mining Tunnels</a>
Photo: Shutterstock

Equities

Emerging Markets

Financing

Commodities

Legal

Markets

LINIF

LTSRF

SVMLF

Malawi Lands $12 Billion Chinese Deal To Boost Mining And Balance Regional Influence

DARE

DARE stock has given up its prior gain. Daré Bioscience shares were trading higher after the company received a $6 million non-dilutive grant installment under its agreement to support DARE-LARC1.

The Delaware Supreme Court has overturned a lower court&#8217;s decision that allowed expert testimony supporting plaintiffs&#8217; claims in a high-profile case alleging that Zantac, or its generic ranitidine, <a target="_blank" href="https://www.benzinga.com/general/biotech/24/05/38946928/gsk-concealed-risk-associated-with-discontinued-heart-burn-drug-zantac-whistleblower-lawsuit-clai" rel="noreferrer noopener">can cause cancer</a>.
The justices concluded that the trial court applied an incorrect legal standard when it ruled that the reliability of expert opinions should be determined by a jury rather than by the judge.
Initially marketed by a forerunner of&nbsp;GSK plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>), Zantac, once a blockbuster heartburn drug, has been sold at different times by companies, including&nbsp;Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), Boehringer Ingelheim, Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>), and <a target="_blank" href="https://www.benzinga.com/general/biotech/23/06/32917283/sanofi-stock-is-trading-higher-today-heres-why" rel="noreferrer noopener">several generic drugmakers</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/politics/25/07/46258994/trumps-big-beautiful-bill-hands-5-billion-win-to-big-pharma-report" rel="noreferrer noopener">Trump&#8217;s &#8216;Big, Beautiful Bill&#8217; Hands $5 Billion Win To Big Pharma: Report</a>
The case centers on nearly 75,000 plaintiffs who claim their cancer diagnoses were caused by exposure to ranitidine, the active ingredient in Zantac, which may degrade into the probable human carcinogen NDMA.
Plaintiffs submitted expert reports linking the drug to ten types of cancer, but the defendants challenged the validity of those reports, questioning the scientific methods used.
The Superior Court <a target="_blank" href="https://courts.delaware.gov/Opinions/Download.aspx?id=382080" rel="noreferrer noopener">denied</a> motions to exclude the expert opinions, citing Delaware&#8217;s &#8220;liberal thrust&#8221; toward admitting expert testimony. It found that any methodological disputes were issues for the jury.
The court also allowed the experts to base their causation claims on studies involving NDMA, rather than requiring a direct link to Zantac itself.
However, the Supreme Court found this reasoning flawed. In its opinion, the court emphasized that Delaware&#8217;s rules on expert evidence align with federal standards, which burden the proponent to prove that testimony is based on sufficient and reliable scientific methods.
The court also faulted the trial judge for improperly framing the central question of general causation. Rather than asking whether Zantac specifically could cause cancer, the lower court allowed experts to rely on data involving NDMA without demonstrating that Zantac exposure levels were comparable to those in the referenced studies.
The Supreme Court ruled that this failed to establish a scientifically valid connection between the product and the alleged harm.
In June, a federal judge ruled that key claims brought by plaintiffs against Patheon Manufacturing Services in the Zantac litigation may move forward, while one claim related to <a href="https://www.benzinga.com/general/biotech/22/12/29989120/relief-to-pfizer-sanofi-as-us-dismisses-several-lawsuits-associated-with-zantac" target="_blank" rel="noreferrer noopener">misrepresentation was dismissed</a>.
In its motion to dismiss, Patheon argued that the plaintiffs&#8217; claims failed on multiple fronts. The company said the plaintiffs did not identify a specific manufacturing defect, asserted that the design defect claim was preempted by federal law, and claimed that negligence was not pled with adequate specificity.
Additionally, Patheon <a href="https://business.cch.com/plsd/InreZantac6-16-25.pdf" target="_blank" rel="noreferrer noopener">contended</a> that no valid misrepresentation claim had been made. However, the court found that plaintiffs had adequately stated distinct claims for manufacturing and design defects.
The judge noted that plaintiffs alleged a flawed manufacturing process that caused ranitidine to form NDMA, a probable carcinogen, or that the manufacturing method contributed to the contamination. The court ruled that, at this stage of litigation, those allegations were sufficient to proceed.
On the negligence claim, the judge concluded that plaintiffs had met the specificity requirements under Rule 9(b), citing detailed allegations that Patheon exposed ranitidine to heat and humidity, leading to its degradation into NDMA.
The court emphasized that the claims were grounded in either violations of federal law or state law duties not solely governed by the FDA, meaning federal preemption did not apply at this stage.
Although the court, in June, agreed with Patheon that the plaintiffs had not asserted a misrepresentation claim, it allowed the remaining claims to proceed.
In May 2024, Pfizer settled 10,000 lawsuits alleging it concealed the cancer risks associated with its Zantac heartburn medication, marking the <a target="_blank" href="https://www.benzinga.com/general/biotech/24/05/38710835/pfizer-agrees-to-settle-over-10-000-lawsuits-about-cancer-risks-associated-with-discontinued-hear" rel="noreferrer noopener">largest resolution in the litigation</a>.&nbsp;
In October 2024, GSK reached agreements with ten plaintiff firms representing approximately 80,000 Zantac product liability&nbsp;cases in the <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41295498/gsk-settles-majority-of-zantac-lawsuits-but-pipeline-doubts-remain" rel="noreferrer noopener">U.S. state courts</a>.
Price Action: PFE stock is down 0.43% at $25.67, and SNY stock is down 1.01% at $48.84 during the premarket session at last check Friday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46363070/bitcoin-sets-all-time-high-at-118909-ethereum-xrp-surge-8-each" target="_blank" rel="noreferrer noopener">Bitcoin Sets All-Time High At $118,909, Ethereum, XRP Surge 8% Each</a></li>
</ul>
Image via Shutterstock

Biotech

Large Cap

Health Care

General

Pfizer, Sanofi Find Relief As Delaware Top Court Rejects Zantac Expert Testimony

Scotiabank analyst Sung Ji Nam upgrades Thermo Fisher Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) from Sector Perform to Sector Outperform and announces $590 price target.

Scotiabank Upgrades Thermo Fisher Scientific to Sector Outperform, Announces $590 Price Target

Guggenheim analyst Gregory Francfort maintains Texas Roadhouse (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXRH#NASDAQ">TXRH</a>) with a Buy and raises the price target from $200 to $210.

TXRH

Guggenheim Maintains Buy on Texas Roadhouse, Raises Price Target to $210

Management

MVBF

MVB Financial Corp. Announces Appointment Of Michael R. Sumbs As CFO, Current CEO Larry F. Mazza To Reassume Role Of President

GAUZ

Gauzy shares are trading higher after disclosing insider purchases of the company stock by the CEO and a long-term investor.

Guggenheim analyst Seamus Fernandez maintains Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) with a Buy and raises the price target from $936 to $942.

Guggenheim Maintains Buy on Eli Lilly, Raises Price Target to $942

HUSA

Houston American Energy Corp. Secures Common Stock Purchase Agreement With Institutional Investor, Establishing Up To $100M Equity Line Of Credit

MicroCloud Hologram Inc. - Ordinary Shares

HOLO

MicroCloud Hologram shares are trading higher after the company announced it purchased more than $200 million worth of Bitcoin.

Press Releases

Aura Biosciences to Participate in the 7th Annual Evercore ISI HealthCONx Conference

Aura Biosciences to Participate in Upcoming Investor Conferences

Aura Biosciences Announces Additional Data from Ongoing Phase 1 Trial in Non-Muscle Invasive Bladder Cancer to be Presented as a Late-Breaking Abstract at the 40th Annual European Association of Urology Congress

Positive Data from Phase 1 Trial of Bel-sar in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) Presented at the 40th Annual European Association of Urology Congress

Earnings

Aura Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights

Aura Biosciences Announces Appointment of Teresa Bitetti to Board of Directors

Aura Biosciences Reports First Quarter 2025 Financial Results and Business Highlights

Aura Biosciences Announces Proposed Public Offering of Common Stock and Warrants

IPOs

Aura Biosciences Announces Pricing of Public Offering of Common Stock and Warrants

Comments

Aura Biosciences

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO